Clinical pearl from #RNL2024 @RheumNow Palmoplantar psoriasis is a great time for first-line JAK inhibitor - Ben Strober, Yale dermatology JAK for atopic dermatitis - extremely rapid responses https://t.co/hHYdGl51n2

"If you are throwing a JAKi at these patients (see below) you are gonna make them better." Dr. Bruce Strober reporting on potential patients/disease states who may respond to JAKi. #RNL2024 @RheumNow https://t.co/bghPuszu5t

#RNL2024 @RheumNow Bruce Strober on JAK in skin diseases - diverse benefits: - PsO - Atopic dermatitis - Alopecia areata - Hidradenitis suppurativa - Vitiligo - Lichen planus any many others https://t.co/I9XHVbFpvQ

“JAKi can be thrown at any inflammatory skin disease and will work!” Dr. B Strober admits he uses many off-label. #RNL2024 @rheumnow https://t.co/nWzW9rMcWL

#RNL2024 @RheumNow Winthrop on Shingrix: Good data at 10 yrs Diminished response in immunocompromised (chemo) Very limited data with autoimmune patients https://t.co/cJitGOWZQt

The 10 year Shingrix data showing continued humoral responses in "normal" patients, with continued long-term efficacy (drops to only 70+%) suggesting we may need to boost at some point. In our rheumatology patients, the efficacy does drop and needs to be evaluated. Dr. Kevin… https://t.co/eHfjtsPv2O https://t.co/K1i5R3ZScV

@RheumNow #RNL2024 Winthrop: JAKi similar for opportunistic disease, but higher risk for Herpes Zoster than other therapies Deucravacitinib - lower HZ reported, but younger age. Will see if this holds case in more studies https://t.co/Nd5LitAI3R

So why should you consider JAKi? Multiple reasons provided by @JointMD including efficacy in domains, it's PO, reasonable safety. #RNL2024 @RheumNow https://t.co/BgFjhb18Ad

Random effect in ACR20 responses in male versus females in PsA. No sex differences in ACR20 responses in patients on JAK/TYK2i . @lihi_eder #RNL2024 @RheumNow https://t.co/fgEORm0nKc

Sex/Gender disparities in rheumatology. @lihi_eder #RNL2024 @RheumNow https://t.co/PB7zPYJHd0

A word on Explicit/ Implicit Bias . Amazing talk and very insightful. @lihi_eder #RNL2024 @RheumNow https://t.co/SGmk5wa9nP

JAKi toxicities of interest: - Zoster - Safety: VTE, MACE, Malignancies - Lab abnormalities including CK, LFT, creatinine, and lipid elevations and cytopenias. @JointMD #RNL2024 @rheumnow https://t.co/u72yz8uLYB